GOSS News and Press, Gossamer Bio Inc. From 08/10/21

The following slide deck was published by Gossamer Bio, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Gossamer Bio, Inc. 2021 Q2 - Results - Earnings Call Presentation

Gossamer Bio, Inc. (GOSS) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Bryan Giraudo - Chief Financial Officer Faheem Hasnain - Chairman, Co-Founder and Chief Executive Officer Richard Aranda - Chief Medical Officer Conference Call Participants Joseph Schwar...

- Seralutinib and GB004 continue to enroll ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively - - Gossamer Announces Seralutinib Open Label Extension Data in PAH Patients - - Gossamer ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its second quarter 2021 financi...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data related to GB004 at t...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that, Richard Aranda, M.D., previously ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Meme stocks will be watched closely again with some investors still looking for an easy ride. As part of a heat check on...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Gossamer Bio (GOSS): Q1 GAAP EPS of -$0.78 misses by $0.01.Cash, cash equivalents and marketable securities of $453M.Press Release For further details see: Gossamer Bio EPS misses by $0.01

– Seralutinib and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively – – Cash, cash equivalents and marketable securities totaled $453 m...